Important Safety Information

Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials,
ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established

You are encouraged to report negative side effects of prescription drugs to the FDA
Visit www.fda.gov/medwatch
or call 1-800-FDA-1088

*30 mg immediate release and 10 mg delayed release beads

 “With the bumps and blemishes from my rosacea, I thought
I’d never land my dream job”

NOW LOOK AT ME

Not an actual patient
ring
ring ring
What is rosacea
Not an actual patient

What is rosacea?

Learn about the signs and symptoms of rosacea, how
it differs from acne, and what factors may trigger your
rosacea

ABOUT ORACEA® (DOXYCYCLINE, USP)
40 MG* CAPSULES 

Take back control of the bumps and blemishes of your rosacea!
Learn more about a once-daily treatment

ORACEA Capsules are indicated for the treatment of only
inflammatory lesions of rosacea in adult patients

*30 mg immediate release and 10 mg delayed release beads

quote

"Now I finally feel I can help
control my rosacea, I take on
new challenges, and I'm loving it!"

quote
Not an actual patient
ring

VISITING YOUR DERMATOLOGIST

Get the most out of your appointment

Putting your rosacea into words isn’t always easy. Support your rosacea conversation by personalizing and downloading a discussion guide

Getting the most out of your visit is all part of the journey to help achieve clearer skin

Not an actual patient
ring ring

YOUR ROSACEA COMMUNITY 

Rosacea Universe

You’re not alone. For ongoing support, tips, and tricks on how to help manage your rosacea symptoms and help you on your journey to achieving clearer skin - make Rosacea Universe your go-to resource. You’ll also find up-to-date information, news, and insights!

Oracea Bottle

STAY CONNECTED

Sign up and
stay up-to-date

Sign up here to receive updates and useful information to help better understand your rosacea

Important Safety Information

Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

*30 mg immediate release and 10 mg delayed release beads

REFERENCES

1. ORACEA [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; 2014